[go: up one dir, main page]

MX2019015348A - Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1). - Google Patents

Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).

Info

Publication number
MX2019015348A
MX2019015348A MX2019015348A MX2019015348A MX2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A
Authority
MX
Mexico
Prior art keywords
ror1
tyrosine kinase
receptor
antibodies against
orphan
Prior art date
Application number
MX2019015348A
Other languages
English (en)
Inventor
Amit Nathwani
Satyen Gohil
Peruta Marco Della
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2019015348A publication Critical patent/MX2019015348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen anticuerpos contra receptor 1 huérfano tipo receptor de tirosina cinasa (ROR1) que unen específicamente un polipéptido ROR1 y su uso. En particular, los anticuerpos monoclonales aislados se describen y su uso en numerosas aplicaciones que incluyen la detección, prevención y tratamiento de cáncer.
MX2019015348A 2017-07-05 2018-07-05 Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1). MX2019015348A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1710835.8A GB201710835D0 (en) 2017-07-05 2017-07-05 ROR1 Antibodies
PCT/GB2018/051914 WO2019008377A1 (en) 2017-07-05 2018-07-05 ANTIBODY ROR1

Publications (1)

Publication Number Publication Date
MX2019015348A true MX2019015348A (es) 2020-07-20

Family

ID=59592560

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015348A MX2019015348A (es) 2017-07-05 2018-07-05 Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).

Country Status (11)

Country Link
US (3) US11466083B2 (es)
EP (1) EP3649152B1 (es)
JP (1) JP7242573B2 (es)
CN (1) CN110891973B (es)
AU (1) AU2018297630B2 (es)
CA (1) CA3068196A1 (es)
DK (1) DK3649152T3 (es)
ES (1) ES3048696T3 (es)
GB (1) GB201710835D0 (es)
MX (1) MX2019015348A (es)
WO (1) WO2019008377A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2022040506A2 (en) * 2020-08-21 2022-02-24 Yale University Nanobody compositions and methods of use of the same
AU2021334677A1 (en) * 2020-08-24 2023-03-02 Epimab Biotherapeutics (Hk) Limited Anti-ROR1 antibodies and related bispecific binding proteins
US20240010721A1 (en) * 2020-09-03 2024-01-11 Harbour Biomed (Shanghai) Co., Ltd Ror1-targeting antibody or antigen-binding fragment thereof, preparation method therefor, and application thereof
CN116981691A (zh) * 2020-11-23 2023-10-31 斯克奥特比奥股份有限公司 抗原结合分子及其用途
WO2022182562A1 (en) * 2021-02-23 2022-09-01 BioLegend, Inc. ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
CN115151572B (zh) * 2021-07-23 2023-09-15 浙江时迈药业有限公司 针对ror1的抗体及其用途
CN113956359B (zh) * 2021-10-29 2022-09-16 叶鑫淼 一种抗体及其在抗肿瘤中的应用
CN118302448A (zh) * 2021-12-28 2024-07-05 江苏恒瑞医药股份有限公司 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途
TW202413422A (zh) * 2022-07-11 2024-04-01 美商翰森生物有限責任公司 抗體、其抗原結合片段及其藥物用途
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
CN118440200B (zh) * 2023-04-21 2025-05-16 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用
WO2025044937A1 (zh) * 2023-08-31 2025-03-06 正大天晴药业集团股份有限公司 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
WO2010124188A1 (en) * 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
US20120282177A1 (en) * 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
DK2513146T3 (en) 2009-12-18 2017-07-31 Kancera Ab Antibodies against ROR1 capable of inducing cell death by CLL
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
HUE053720T2 (hu) 2011-01-14 2021-07-28 Univ California ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
KR102264290B1 (ko) 2012-08-20 2021-06-10 프레드 헛친슨 켄서 리서치 센터 세포 면역요법을 위한 방법 및 조성물
MX362456B (es) * 2012-08-24 2019-01-18 Univ California Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
AU2015295349B2 (en) * 2014-07-29 2020-09-24 Cellectis ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
SG11201701809UA (en) 2014-09-08 2017-04-27 Nat Cancer Ct Cancer cell-specific antibody, anticancer drug and cancer testing method
AU2015329966A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1 for use in the treatment of ovarian cancer
ES2850325T3 (es) 2014-10-09 2021-08-27 Engmab Sarl Anticuerpos biespecíficos contra CD3epsilon y ROR1
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
CN107428833B (zh) * 2015-01-16 2021-11-02 朱诺治疗学股份有限公司 Ror1特异性抗体和嵌合抗原受体
AU2016214492B2 (en) 2015-02-02 2020-05-07 Kancera Ab 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity
EP3842072A1 (en) * 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
JP2019502363A (ja) 2015-10-30 2019-01-31 エヌビーイー セラピューティクス アクチェン ゲゼルシャフト 抗ｒｏｒ１抗体
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
AU2017209099A1 (en) 2016-01-22 2018-08-02 Janssen Biotech, Inc. Anti-ROR1 antibodies, ROR1 x CD3 bispecific antibodies, and methods of using the same
UY37127A (es) 2016-02-17 2017-08-31 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
KR102466810B1 (ko) 2016-07-11 2022-11-11 칸세라 아베 포유류 티로신 키나제 ror1 활성의 저해제로서 유용한 2-페닐이미다조[4,5-b]피리딘-7-아민 유도체
US20200338210A1 (en) 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
BR112019024654A2 (pt) 2017-05-23 2020-06-09 Dragonfly Therapeutics Inc proteína de ligação nkg2d, cd16 e ror1 ou ror2
JP7245239B2 (ja) 2017-06-23 2023-03-23 ベロスバイオ・インコーポレイテッド Ｒｏｒ１抗体免疫複合体
US11987635B2 (en) 2017-06-25 2024-05-21 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Anti-4-1BB antibodies and methods of making and using thereof
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
US20210139579A1 (en) 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
WO2019030240A1 (en) 2017-08-07 2019-02-14 Nbe-Therapeutics Ag ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE
CN117756946A (zh) 2017-11-03 2024-03-26 莱蒂恩技术公司 用于用抗ror1免疫治疗来治疗癌症的组合物和方法
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도

Also Published As

Publication number Publication date
EP3649152A1 (en) 2020-05-13
CN110891973B (zh) 2023-06-27
JP7242573B2 (ja) 2023-03-20
CN110891973A (zh) 2020-03-17
JP2020530272A (ja) 2020-10-22
EP3649152B1 (en) 2025-10-08
CA3068196A1 (en) 2019-01-10
US20200354448A1 (en) 2020-11-12
US20230220073A1 (en) 2023-07-13
ES3048696T3 (en) 2025-12-11
GB201710835D0 (en) 2017-08-16
AU2018297630A1 (en) 2020-01-16
DK3649152T3 (da) 2025-11-10
WO2019008377A1 (en) 2019-01-10
US20250066472A1 (en) 2025-02-27
AU2018297630B2 (en) 2025-03-06
US11466083B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
MX2019015348A (es) Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
EA202091540A1 (ru) Антитела к lilrb2
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
EA202090204A1 (ru) Анти-cd137 антитела
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
NZ739750A (en) Anti-tigit antibodies and methods of use
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
TN2017000010A1 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use.
MX2019015349A (es) Anticuerpos biespecificos para receptor 1 huerfano tipo receptor de tirosina cinasa (ror1) y grupo de diferenciacion 3 (cd3).
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
IL257274B (en) Compositions and methods for treating cancers associated with etbr activation
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX2020005364A (es) Anticuerpos anti-ox40 y usos de los mismos.
MX2024003627A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.
MA55558A (fr) Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка